Gorber S, Singh H, Pottie K, et al. Process for guideline development by the reconstituted Canadian Task Force on Preventive Health Care. Can Med Assoc J. 2012;184(14):1575–81.
Lenzer J. Is the United States preventive services task force still a voice of caution? BMJ. 2017;356:j743.
McGlynn E, Asch S, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348(26):2635–45.
Shenson D, Adams M, Bolen J, et al. Routine checkups don’t ensure that seniors get preventive services. J Fam Pract. 2011;60(1):E1–10.
Smith H, Herbert C. Preventive practice among primary care physicians in British Columbia: relation to recommendations of the Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1993;149(12):1795–800.
Ogden L, Richards C, Shenson D. Clinical preventive services for older adults: the interface between personal health care and public health services. Am J Public Health. 2012;102(3):419–25.
Pollack K, Krause K, Yarnall K, et al. Estimated time spent on preventive services by primary care physicians. BMC Health Serv Res. 2008;8(245). https://doi.org/10.1186/1472-6963-8-245.
Yarnall K, Pollack K, Ostbye T, et al. Primary care: is there enough time for prevention? Am J Public Health. 2003;93(4):635–41.
BC Clinical Prevention Policy Review Committee. A lifetime of Prevention. 2009. Available at https://www2.gov.bc.ca/assets/gov/health/about-bc-s-health-care-system/health-priorites/lifetime-prevention-schedule/cppr-lifetime-prevention-report-2009.pdf. Accessed Mar 2021.
Farley T, Dalal M, Mostashari F, et al. Deaths preventable in the U.S. by improvements in the use of clinical preventive services. Am J Prev Med. 2010;38(6):600–9.
Maciosek M, LaFrance A, Dehmer S, et al. Updated priorities among effective clinical preventive services. Ann Fam Med. 2017;15(1):14–22.
Maciosek M, Coffield A, McGinnis M, et al. Methods for priority setting among clinical preventive services. Am J Prev Med. 2001;21(1):10–9.
Coffield A, Maciosek M, McGinnis J, et al. Priorities among recommended clinical preventive services. Am J Prev Med. 2001;21(1):1–9.
Maciosek M, Coffield A, Edwards N, et al. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med. 2006;31(1):52–61.
Technical reports and additional information about the Lifetime Prevention Schedule are available online at https://www2.gov.bc.ca/gov/content/health/about-bc-s-health-care-system/health-priorities/lifetime-prevention. Accessed Mar 2021.
Lewandowski RE, O’Connor B, Bertagnolli A, et al. Screening for and diagnosis of depression among adolescents in a large health maintenance organization. Psychiatr Serv. 2016;67(6):636–41.
Lefèvre Å, Lundqvist P, Drevenhorn E, et al. Parents’ experiences of parental groups in Swedish child health-care: do they get what they want? J Child Health Care. 2016;20(1):46–54.
Hillman JB, Corathers SD, Wilson SE. Pediatricians and screening for obesity with body mass index: does level of training matter? Public Health Rep. 2009;124(4):561–7.
Arlene Cristall, Provincial Lead. The centre for healthy weights – Shapedown BC. 2020. Personal communication.
Jamal A, Dube S, Babb S, et al. Tobacco use screening and cessation assistance during physician office visits among persons aged 11–21 years—National Ambulatory Medical Care Survey, United States, 2004–2010. Morb Mortal Wkly Rep. 2014;63(2):71–9.
Buckingham S, John J. Recruitment and participation in preschool and school-based fluoride varnish pilots–the south central experience. Br Dent J. 2013;215(E8):1–4.
Veiga N, Pereira C, Ferreira P, et al. Prevalence of dental caries and fissure sealants in a Portuguese sample of adolescents. PLoS One. 2015;10(3):1–12.
National Cancer Institute. Screening and risk factors table: had a mammogram in the past 2 years. 2017. Available at https://statecancerprofiles.cancer.gov/risk/index.php. Accessed July 2017.
National Cancer Institute. Screening and risk factors table: Pap test in past 3 years, no hysterectomy. 2017. Available at https://statecancerprofiles.cancer.gov/risk/index.php. Accessed July 2017.
National Cancer Institute. Screening and risk factors table. 2017. Available at https://statecancerprofiles.cancer.gov/risk/index.php. Accessed Aug 2017.
Huo J, Shen C, Volk R, et al. Use of CT and chest radiography for lung cancer screening before and after publication of screening guidelines: intended and unintended uptake. J Am Med Assoc Intern Med. 2017;177(3):439–41.
Godwin M, Williamson T, Khan S, et al. Prevalence and management of hypertension in primary care practices with electronic medical records: a report from the Canadian Primary Care Sentinel Surveillance Network. Can Med Assoc J Open. 2015;3(1):E76–82.
England PH. Public health outcomes framework. 2017. Available at http://www.phoutcomes.info/search/health%20check#pat/6/ati/102/par/E12000004. Accessed Aug 2017.
Chang K, Lee J, Vamos E, et al. Impact of the National Health Service Health Check on cardiovascular disease risk: a difference-in-differences matching analysis. Can Med Assoc J. 2016;188(10):E228–38.
Helin-Salmivaara A, Lavikainen P, Korhonen M, et al. Long-term persistence with statin therapy: a nationwide register study in Finland. Clin Ther. 2008;30(1):2228–40.
Hellgren M, Petzold M, Björkelund C, et al. Feasibility of the FINDRISC questionnaire to identify individuals with impaired glucose tolerance in Swedish primary care. A cross-sectional population-based study. Diabet Med. 2012;29(12):1501–5.
Van den Donk M, Sandbaek A, Borch-Johnsen K, et al. Screening for type 2 diabetes. Lessons from the ADDITION-Europe study. Diabet Med. 2011;28(11):1416–24.
Rui P, Hing E, Okeyode T. National ambulatory medical care survey: 2014 state and national summary tables. Available at http://www.cdc.gov/nchs/ahcd/ahcd_products.htm. Accessed Aug 2017.
Delatte R, Cao H, Meltzer-Brody S, et al. Universal screening for postpartum depression: an inquiry into provider attitudes and practice. Am J Obstet Gynecol. 2009;200(5):e63–e4.
Amarnath A, Franks P, Robbins J, et al. Underuse and overuse of osteoporosis screening in a regional health system: a retrospective cohort study. J Gen Intern Med. 2015;12(30):1733–40.
Jacomelli J, Summers L, Stevenson A, et al. Impact of the first 5 years of a national abdominal aortic aneurysm screening programme. Br J Surg. 2016;103(9):1125–31.
Van Handel M, Branson B. Monitoring HIV testing in the United States: consequences of methodology changes to national surveys. PLoS One. 2015;10(4):1–12.
England PH. Sexually transmitted infections (STIs): annual data tables. 2017. Available at https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables. Accessed Aug 2017.
Health Protection Agency. HIV in the United Kingdom: 2012 report. 2012. Available at http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317137200016. Accessed Aug 2017.
Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2015. Atlanta: U.S. Department of Health and Human Services; 2016. Available online at https://www.cdc.gov/std/stats15/STD-Surveillance-2015-print.pdf. Accessed Aug 2017
Cullen B, Hutchison S, Cameron S, et al. Identifying former injecting drug users infected with hepatitis C: an evaluation of a general practice-based case-finding intervention. J Public Health. 2012;34(1):14–23.
Tyler C, Warner L, Gavin L, et al. Receipt of reproductive health services among sexually experienced persons aged 15–19 years—national survey of family growth, United States, 2006–2010. Morb Mortal Wkly Rep. 2014;63(2):2–5.
Kruger J, Shaw L, Kahende J, et al. Health care providers’ advice to quit smoking, national health interview survey, 2000, 2005, and 2010. Prev Chronic Dis. 2012;9:E130.
Bradley K, Williams E, Achtmeyer C, et al. Implementation of evidence-based alcohol screening in the Veterans Health Administration. Am J Manag Care. 2006;12:597–606.
Wangberg SC. Norwegian midwives’ use of screening for and brief interventions on alcohol use in pregnancy. Sex Reprod Healthc. 2015;6(3):186–90.
McCarty D, Gu Y, Renfro S, et al. Access to treatment for alcohol use disorders following Oregon’s health care reforms and Medicaid expansion. J Subst Abus Treat. 2018;94:24–8.
Fitzpatrick S, Stevens V. Adult obesity management in primary care, 2008–2013. Prev Med. 2017;99:128–33.
Fitzpatrick S, Dickins K, Avery E, et al. Effect of an obesity best practice alert on physician documentation and referral practices. Transl Behav Med. 2017:1–10.
Stevens J, Ballesteros M, Mack K, et al. Gender differences in seeking care for falls in the aged Medicare population. Am J Prev Med. 2012;43(1):59–62.
Kantor E, Rehm C, Du M, et al. Trends in dietary supplement use among US adults from 1999-2012. J Am Med Assoc. 2016;316(14):1464–74.
Fiscella K, Winters P, Mendoza M, et al. Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease? J Gen Intern Med. 2013;30(2):155–60.
Malayala S, Raza A. Compliance with USPSTF recommendations on aspirin for prevention of cardiovascular disease in men. Int J Clin Pract. 2016;70(11):898–906.
Canadian Task Force on Preventive Health Care. Procedure manual. 2014. Available at https://canadiantaskforce.ca/wp-content/uploads/2016/12/procedural-manual-en_2014_Archived.pdf. Accessed Mar 2021.
Kurth A, Krist A, Borsky A, et al. U.S. Preventive Services Task Force methods to communicate and disseminate clinical preventive services recommendations. Am J Prev Med. 2018;54(1S1):S81–7.
See http://www.bccdc.ca/health-professionals/clinical-resources/communicable-disease-control-manual/immunization. Accessed Mar 2021.
See http://www.perinatalservicesbc.ca/health-professionals/guidelines-standards. Accessed Mar 2021.
Forman-Hoffman V, McClure E, McKeeman J, et al. Screening for major depressive disorder in children and adolescents: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2016;164(5):342–9.
Chung M, Raman G, Trikalinos T, et al. Interventions in primary care to promote breastfeeding: an evidence review for the US Preventive Services Task Force. Ann Intern Med. 2008;149(8):565–82.
Canadian Task Force on Preventive Health Care. Recommendations for growth monitoring, and prevention and management of overweight and obesity in children and youth in primary care. Can Med Assoc J. 2015;187(6):411–21.
US Preventive Services Task Force. Screening for obesity in children and adolescents: US Preventive Services Task Force recommendation statement. JAMA. 2017;317(23):2417–26.
Canadian Task Force on Preventive Health Care. Recommendations on behavioural interventions for the prevention and treatment of smoking among school-aged children and youth. Can Med Assoc J. 2017;189(8):e310–6.
Marinho V, Worthington H, Walsh T, et al. Fluoride varnishes for preventing dental caries in children and adolescents. Cochrane Database Syst Rev. 2013. Available from https://doi.org/10.1002/14651858.CD002279.pub2.
Ahovuo-Saloranta A, Forss H, Walsh T, et al. Sealants for preventing dental decay in the permanent teeth. Cochrane Database Syst Rev. 2013. Available from https://doi.org/10.1002/14651858.CD001830.pub4.
Fitzpatrick-Lewis D, Hodgson N, Ciliska D, et al. Breast cancer screening. 2011. Available at http://canadiantaskforce.ca/wp-content/uploads/2012/09/Systematic-review.pdf?0136ff.
Peirson L, Fitzpatrick-Lewis D, Ciliska D, et al. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev. 2013;2(35). Available from https://link.springer.com/article/10.1186/2046-4053-2-35.
Ronco G, Dillner J, Elfström K, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–32.
Canadian Task Force on Preventive Health Care. Recommendations on screening for colorectal cancer in primary care. Can Med Assoc J. 2016;188(5):340–8.
National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.
Law M, Morris J, Wald N. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J. 2009;338. https://doi.org/10.1136/bmj.b1665.
Chou R, Dana T, Blazina I, et al. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. J Am Med Assoc. 2016;316(19):2008–24.
Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet. 2010;375(9723):1365–74.
Colman I, Zeng Y, Ataullahjan A, et al. The association between antidepressant use and depression eight years later: a national cohort study. J Psychiatr Res. 2011;45(8):1012–8.
O’Connor E, Rossom RC, Henninger M, et al. Primary care screening for and treatment of depression in pregnant and postpartum women: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;315(4):388–406.
Curry S, Krist A, Owens D, et al. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. J Am Med Assoc. 2018;319(24):2521–31.
Patrick A, Brookhart M, Losina E, et al. The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab. 2010;95(7):3251–9.
Girguis-Blake J, Beil T, Sun X et al. Primary care screening for abdominal aortic aneurysm: a systematic evidence review for the US Preventive Services Task Force. Evidence synthesis no. 109. 2014: Available at https://www.ncbi.nlm.nih.gov/books/NBK184793/.
Cohen M, Chen Y, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
Anglemyer A, Rutherford G, Horvath T, et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2013. Available from https://doi.org/10.1002/14651858.CD009153.pub3.
Hu D, Hook E, Goldie S. Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis. Ann Intern Med. 2004;141(7):501–13.
Jacobson I, Lawitz E, Gane E, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153(1):113–22.
Feld J, Jacobson I, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607.
Foster G, Afdhal N, Roberts S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–17.
Zeuzem S, Ghalib R, Reddy K, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13.
Asselah T, Kowdley K, Zadeikis N, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417–26.
Zeuzem S, Foster G, Wang S, et al. Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–69.
O’Connor E, Lin J, Burda B, et al. Behavioral sexual risk-reduction counselling in primary care to prevent sexually transmitted infections: an updated systematic evidence review for the US Preventive Services Task Force. Ann Intern Med. 2014;161(12):874.
Smith A, Chapman S. Quitting smoking unassisted: the 50-year research neglect of a major public health phenomenon. J Am Med Assoc. 2014;311(2):137–8.
Fiore M, Jaen C, Baker T, et al. Clinical practice guideline. Treating tobacco use and dependence: 2008 update: U.S. Department of Health and Human Services; 2008. Available at http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/tobacco/clinicians/treating_tobacco_use08.pdf
Curry SJ, Krist AH, Owens DK, et al. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force recommendation statement. J Am Med Assoc. 2018;320(18):1899–909.
Peirson L, Douketis J, Ciliska D, et al. Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis. Can Med Assoc Open Access J. 2014;2(4):e306–e17.
Michael Y, Whitlock E, Lin J, et al. Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2010;153(12):815–25.
Guirguis-Blake J, Evans C, Senger C, et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164(12):804–13.
Chubak J, Whitlock E, Williams S, et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164(12):814–25.
De-Regil L, Peña-Rosas J, Fernández-Gaxiola A, et al. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2015. Available from https://doi.org/10.1002/14651858.CD007950.pub3.
Salomon J, Haagsma J, Davis A, et al. Disability weights for the global burden of diseases 2013 study. Lancet Glob Health. 2015;3:e712–23.
Institute for Health Metrics and Evaluation. GBD 2016 sequelae, health states, health state lay descriptions, and disability weights. Available online at http://ghdx.healthdata.org/record/global-burden-disease-study-2016-gbd-2016-disability-weights. Accessed Mar 2021.
Sullivan P, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak. 2006;26(4):410–20.
Sullivan PW, Slejko JF, Sculpher MJ, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Mak. 2011;31(6):800–4.
Thompson A, Guthrie B, Payne K. Do pills have no ills? Capturing the impact of direct treatment disutility. PharmacoEconomics. 2016;34(4):333–6.
Hutchins R, Pignone M, Sheridan S, et al. Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey. Br Med J Open. 2015;5(e006505):1–9.
Hutchins R, Viera AJ, Sheridan SL, et al. Quantifying the utility of taking pills for cardiovascular prevention. Circ Cardiovasc Qual Outcomes. 2015;8(2):155–63.
Fitzmaurice C, Allen C, Barber R, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. J Am Med Assoc Oncol. 2017;3(4):524–48.
Dormal V, Bremhorst V, Lannoy S, et al. Binge drinking is associated with reduced quality of life in young students: a pan-European study. Drug Alcohol Depend. 2018;193:48–54.
Schousboe J, Kerlikowske K, Loh A, et al. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011;155(1):10–20.
Insinga R, Glass A, Myers E, et al. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Mak. 2007;27(4):414–22.
Krueger H, Lindsay P, Cote R, et al. Cost avoidance associated with optimal stroke care in Canada. Stroke. 2012;43(8):2198–206.
Chapman K, Ernst P, Grenville A, et al. Control of asthma in Canada: failure to achieve guideline targets. Can Respir J. 2001;8(Suppl A):35A–40A.
Whiteford H, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet. 2013;382(9904):1575–86.
Stade B, Stevens B, Ungar W, et al. Health-related quality of life of Canadian children and youth prenatally exposed to alcohol. Health Qual Life Outcomes. 2006;4:81.
Campbell H, Stokes E, Bargo D, et al. Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. Br Med J Open. 2015;5(4):e007230.
Hsu PC, Federico CA, Krajden M, et al. Health utilities and psychometric quality of life in patients with early-and late-stage hepatitis C virus infection. J Gastroenterol Hepatol. 2012;27(1):149–57.
Ratcliffe J, Longworth L, Young T, et al. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl. 2002;8(3):263–70.
Ul-Haq Z, Mackay D, Fenwick E, et al. Meta-analysis of the association between body mass index and health-related quality of life among children and adolescents, assessed using the pediatric quality of life inventory index. J Pediatr. 2013;162(2):280–6.
Lamb T, Frew E, Ives N, et al. Mapping the paediatric quality of life inventory (PedQL™) generic core scales onto the child health utility index-9 dimension (CHU-9D) score for economic evaluation in children. PharmacoEconomics. 2018;36:451–65.
Maheswaran H, Petrou S, Rees K, et al. Estimating EQ-5D utility values for major health behavioural risk factors in England. J Epidemiol Community Health. 2013;67(1):172–80.
Bertram M, Norman R, Kemp L, et al. Review of the long-term disability associated with hip fractures. Inj Prev. 2011;17:365–70.
Kanis J, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001;12(5):417–27.
Grosse S, Flores A, Ouyang L, et al. Impact of spina bifida on parental caregivers: findings from a survey of Arkansas families. J Child Fam Stud. 2009;18(5):574–81.
Rehm J, Gnam W, Popova S, et al. The costs of alcohol, illegal drugs, and tobacco in Canada, 2002. J Stud Alcohol Drugs. 2007;68(6):886–95.
Grosse S, Berry R, Tilford J, et al. Retrospective assessment of cost savings from prevention: folic acid fortification and spina bifida in the US. Am J Prev Med. 2016;50(5S1):S74–80.
Statistics Canada. Average hourly wages of employees by selected characteristics and occupation, unadjusted data, by province (monthly) (British Columbia). 2017. Available at http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr69k-eng.htm. Accessed Mar 2021.
Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6(1):51–9.
The Campbell and Cochrane Economics Methods Group and Evidence for Policy and Practice Information and Coordinating Centre. CCEMG - EPPI-centre cost converter. 2021. Available at https://eppi.ioe.ac.uk/costconversion/. Accessed Dec 2021.
Papanicolas I, Woskie L, Jha A. Health care spending in the United States and other high-income countries. JAMA. 2018;319(10):1024–39.
Anderson G, Reinhardt U, Hussey P, et al. It’s the prices, stupid: why the United States is so different from other countries. Health Aff. 2003;22(3):89–105.
Reinhardt U. Why does US health care cost so much? (part I). 2008. Available at https://economix.blogs.nytimes.com/2008/11/14/why-does-us-health-care-cost-so-much-part-i/. Accessed July 2017.
Ministry of Health. Medical services commission payment schedule. 2016. Available at http://www2.gov.bc.ca/assets/gov/health/practitioner-pro/medical-services-plan/msc-payment-schedule-december-2016.pdf.
Giardina S, Pane B, Spinella G, et al. An economic evaluation of an abdominal aortic aneurysm screening program in Italy. J Vasc Surg. 2011;54(4):938–46.
Silverstein M, Pitts S, Chaikof E, et al. Abdominal aortic aneurysm (AAA): cost-effectiveness of screening, surveillance of intermediate-sized AAA, and management of symptomatic AAA. Bayl Univ Med Cent Proc. 2005;18(4):345–67.
Burgers L, Vahl A, Severens J, et al. Cost-effectiveness of elective endovascular aneurysm repair versus open surgical repair of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2016;52(1):29–40.
Visser J, van Sambeek M, Hunink M, et al. Acute abdominal aortic aneurysms: cost analysis of endovascular repair and open surgery in hemodynamically stable patients with 1-year follow-up. Radiology. 2006;240(3):681–9.
Svensjö S, Mani K, Björck M, et al. Screening for abdominal aortic aneurysm in 65-year-old men remains cost-effective with contemporary epidemiology and management. Eur J Vasc Endovasc Surg. 2014;47(4):357–65.
H. Krueger & Associates Inc. The economic burden of risk factors in British Columbia: excess weight, tobacco smoking, alcohol use, physical inactivity and low fruit and vegetable consumption. Vancouver: Provincial Health Services Authority, Population and Public Health Program; 2017.
Canadian Substance Use Costs and Harms Scientific Working Group. Canadian substance use costs and harms in the provinces and territories (2007 – 2014). Ottawa: Prepared by the Canadian Institute for Substance Use Research and the Canadian Centre on Substance Use and Addiction; 2018.
Stade B, Ali A, Bennett D, et al. The burden of prenatal exposure to alcohol: revised measurement of cost. Can J Clin Pharmacol. 2009;16(1):e91–e102.
Barbeau M, Lalonde H. Burden of atopic dermatitis in Canada. Int J Dermatol. 2006;45(1):31–6.
BC Cancer Agency. Screening mammography program: 2016 annual report. 2016. Available at http://www.bccancer.bc.ca/screening/Documents/SMP_Report-AnnualReport2016.pdf.
Gocgun Y, Banjevic D, Taghipour S, et al. Cost-effectiveness of breast cancer screening policies using simulation. Breast. 2015;24(4):440–8.
de Oliveira C, Bremner K, Pataky R, et al. Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. Can Med Assoc J Open. 2013;1(1):E1–8.
Wai E, Trevisan C, Taylor S, et al. Health system costs of metastatic breast cancer. Breast Cancer Res Treat. 2001;65(3):233–40.
Broekx S, Den Hond E, Torfs R, et al. The costs of breast cancer prior to and following diagnosis. Eur J Health Econ. 2011;12(4):311–7.
Kulasingam S, Rajan R, St Pierre Y, et al. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Med. 2009;7(1):69.
Brisson M, Van de Velde N, De Wals P, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25(29):5399–408.
Krahn M, McLauchlin M, Pham B, et al. Liquid-based techniques for cervical cancer screening: systematic review and cost-effectiveness analysis. 2008. Available at https://www.cadth.ca/sites/default/files/pdf/333_LBC-Cervical-Cancer-Screenin_tr_e.pdf. Accessed Aug 2017.
Popadiuk C, Gauvreau C, Bhavsar M, et al. Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada. Curr Oncol. 2016;23(Supp.1):S56–63.
Sander B, Wong W, Yeung M, et al. The cost-utility of integrated cervical cancer prevention strategies in the Ontario setting–can we do better? Vaccine. 2016;34(16):1936–44.
Mariotto A, Robin Y, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28.
Cressman S, Lam S, Tammemagi MC, et al. Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. J Thorac Oncol. 2014;9(10):1449–58.
Ministry of Health. Cardiovascular disease – primary prevention. 2014. Available at http://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/cvd.pdf.
See BC Reference Drug Program. Available online at http://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/reference-drug-program.
Pandya A, Sy S, Cho S, et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. J Am Med Assoc. 2015;314(2):142–50.
Dehmer S, Maciosek M, LaFrance A, et al. Health benefits and cost-effectiveness of asymptomatic screening for hypertension and high cholesterol and aspirin counseling for primary prevention. Ann Fam Med. 2017;15(1):23–36.
Gloede T, Halbach S, Thrift A, et al. Long-term costs of stroke using 10-year longitudinal data from the north East Melbourne stroke incidence study. Stroke. 2014;45(11):3389–94.
Sadatsafavi M, Lynd L, Marra C, et al. Direct health care costs associated with asthma in British Columbia. Can Respir J. 2010;17(2):74–80.
Bartick M, Reinhold A. The burden of suboptimal breastfeeding in the United States: a pediatric cost analysis. Pediatrics. 2010;125(5):e1048–e56.
BC Ministry of Social Development and Poverty Reduction. Dental supplement. 2017. Available online at https://www2.gov.bc.ca/assets/gov/family-and-social-supports/income-assistance/on-assistance/schedule-dentist.pdf.
Canadian Institute for Health Information. Treatment of preventable dental cavities in preschoolers: a focus on day surgery under general anesthesia. 2013. Available at https://secure.cihi.ca/free_products/Dental_Caries_Report_en_web.pdf.
Morgan S, Smolina K, Mooney D, et al. The Canadian Rx Atlas, third edition: UBC Centre for Health Services and Policy Research; 2013. Available at http://www.chspr.ubc.ca/sites/default/files/file_upload/publications/2013/RxAtlas/canadianrxatlas2013.pdf
Pacific Blue Cross. Pharmacy compass. 2018. Available at https://www.pac.bluecross.ca/pharmacycompass.
Wright D, Katon WJ, Ludman E, et al. Association of adolescent depressive symptoms with health care utilization and payer-incurred expenditures. Acad Pediatr. 2016;16(1):82–9.
Shepard D, Gurewich D, Lwin AK, et al. Suicide and suicidal attempts in the United States: costs and policy implications. Suicide Life Threat Behav. 2016;46(3):352–62.
Clayton D, Barcel A. The cost of suicide mortality in New Brunswick, 1996. Chronic Dis Can. 1999;20(2):89–95.
Kinchin I, Doran CM. The cost of youth suicide in Australia. Int J Environ Res Public Health. 2018;15(4):672–82.
BC Ministry of Health. MSP fee-for-service payment analysis. 2012/2013 - 2016/2017. Available online at https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/medical-services-plan/ffs_complete.pdf.
Frick K, Gower E, Kempen J, et al. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol. 2007;125(4):544–50.
O’Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res. 2003;3(1):7.
Comay D, Marshall J. Resource utilization for acute lower gastrointestinal hemorrhage: the Ontario GI bleed study. Can J Gastroenterol. 2002;16(10):677–82.
Ball T, Wright A. Health care costs of formula-feeding in the first year of life. Pediatrics. 1999;103(Suppl. 1):870–6.
El Saadany S, Coyle D, Giulivi A, et al. Economic burden of hepatitis C in Canada and the potential for prevention. Eur J Health Econ. 2005;6:159–65.
Myers R, Krajden M, Bilodeau M, et al. Burden of disease and cost of chronic hepatitis C virus infection in Canada. Can J Gastroenterol Hepatol. 2014;28(5):243–50.
Douglass CH, Pedrana A, Lazarus JV, et al. Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Med. 2018;16(1):175.
Hurley R. Slashed cost of hepatitis C drugs spurs drive to eliminate the disease. BMJ. 2018;361:k1679.
Williams J, Miners A, Harris R, et al. The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the national health service health check programme in England. Value Health. 2019;22(11):1248–56.
Taylor M, Grieg P, Detsky A, et al. Factors associated with the high cost of liver transplantation in adults. Can J Surg. 2002;45(6):425–34.
Kingston-Riechers J. The economic cost of HIV/AIDS in Canada: Canadian AIDS Society; 2011. Available online at http://www.cdnaids.ca/files.nsf/pages/economiccostofhiv-aidsincanada/$file/Economic%20Cost%20of%20HIV-AIDS%20in%20Canada.pdf
Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment – United States, 2003. MMWR Wkly. 2003;53(03):57–9.
Jaquier M, Klein A, Boltshauser E. Spontaneous pregnancy outcome after prenatal diagnosis of anencephaly. BJOG. 2006;113(8):951–3.
Canadian Institute for Health Information. Patient cost estimator. Available online at https://www.cihi.ca/en/spending-and-health-workforce/spending/patient-cost-estimator.
Karen Strange, Project Director. Generation Health, Childhood Obesity Foundation. 2020. Personal communication.
Gustafson A, Khavjou O, Stearns SC, et al. Cost-effectiveness of a behavioral weight loss intervention for low-income women: the weight-wise program. Prev Med. 2009;49(5):390–5.
Krukowski R, Tilford J, Harvey-Berino J, et al. Comparing behavioral weight loss modalities: incremental cost-effectiveness of an internet-based versus an in-person condition. Obesity. 2011;19(8):1629–35.
Neumann A, Schwarz P, Lindholm L. Estimating the cost-effectiveness of lifestyle intervention programmes to prevent diabetes based on an example from Germany: Markov modelling. Cost Eff Resour Alloc. 2011;9(1):17.
B.C. Ministry of Health, Health Sector Information, Analysis & Reporting Division. MSP fee-for-service payment analysis 2012/2013 - 2016/2017. 2017. Available at https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/medical-services-plan/ffs_complete.pdf.
Hopkins R, Burke N, Von Keyserlingk C, et al. The current economic burden of illness of osteoporosis in Canada. Osteoporos Int. 2016;27(10):3023–32.
Coyte P, Asche C, Elden L. The economic cost of otitis media in Canada. Int J Pediatr Otorhinolaryngol. 1999;49(1):27–36.
Owusu-Edusei K Jr, Chesson HW, Gift TL, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis. 2013;40(3):197–201.
BC Ministry of Health. Effective pharmacological aids to smoking cessation. 2011. Available at http://www.health.gov.bc.ca/pharmacare/pdf/sc-prod-info.pdf.
Canadian Agency for Drugs and Technologies in Health Methods and Guidelines. Guidelines for the economic evaluation of health technologies. Canada; 2017. Available at https://www.cadth.ca/guidelines-economic-evaluation-health-technologies-canada-4th-edition. Accessed Mar 2021
The National Institute for Health and Care Excellence (NICE). Methods for the development of NICE public health guidance (third edition). Available at https://www.nice.org.uk/process/pmg4/chapter/incorporating-health-economics. Accessed Mar 2021.
Krueger H, Krueger J, Koot J. Variation across Canada in the economic burden attributable to excess weight, tobacco smoking and physical inactivity. Can J Public Health. 2015;106(4):e171–7.
Krueger H, Koot J, Rasali D, et al. Regional variation in the economic burden attributable to excess weight, physical inactivity and tobacco smoking across British Columbia. Health Promot Chronic Dis Prev Can. 2016;36(4):76–86.
Marmot M, Goldblatt P, Allen J, et al. Fair society healthy lives (the Marmot review): Institute of Health Equity; 2010. Available online at http://www.instituteofhealthequity.org/resources-reports/fair-society-healthy-lives-the-marmot-review. Accessed Mar 2021
Fagg J, Chadwick P, Cole T, et al. From trial to population: a study of a family-based community intervention for childhood overweight implemented at scale. Int J Obes. 2014;38(10):1343–9.
Margaret Yandel, Policy Lead. Office of the Provincial Dietitian. 2020. Personal communication.
Moyer VA. Screening for and management of obesity in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(5):373–8.
Enderling H, Wolkenhauer O. Are all models wrong? Comput Syst Oncol. 2021;1:e1008.
Platt L, Melendez-Torres G, O’Donnell A, et al. How effective are brief interventions in reducing alcohol consumption: Do the setting, practitioner group and content matter? Findings from a systematic review and meta-regression analysis. BMJ Open. 2016;6:e011473.
GPSC Services Committee. Prevention incentives. 2018. Available online at http://www.gpscbc.ca/sites/default/files/uploads/GPSC%20Billing%20Guide%20-%20Prevention%20201801.pdf. Accessed Mar 2021.
BC Cancer. B.C. launches lung cancer screening program – the first in Canada. 2020. Available online at http://www.bccancer.bc.ca/about/news-stories/news/2020/b-c-launches-lung-cancer-screening-program-%E2%80%93-the-first-in-canada. Accessed Mar 2021.